PharmaShots | Incisive News in 3 Shots

Subscribe Now

myasthenia gravis

UCB to Acquire Ra Pharma to Improve Therapies for Patients with Myasthenia Gravis and Other Rare Diseases

UCB to Acquire Ra Pharma to Improve Therapies for Patients with Myasthenia Gravis and Other Rare Diseases

October 10, 2019

Johnson & Johnson Reports the Results from 2 Trials of Nipocalimab to Treat Generalized Myasthenia Gravis (gMG) and Sjögren’s Disease (SjD)

Johnson & Johnson Reports the Results from 2 Trials of Nipocalimab to Treat Generalized Myasthenia Gravis (gMG) and Sjögren’s Dise...

February 7, 2024

Insights+: EMA Marketing Authorization of New Drugs in December 2023

Insights+: EMA Marketing Authorization of New Drugs in December 2023

January 23, 2024

argenx’s Vyvdura Injection Receives MHLW’s Approval for Generalized Myasthenia Gravis

argenx’s Vyvdura Injection Receives MHLW’s Approval for Generalized Myasthenia Gravis

January 18, 2024

UCB Receives the EC’s Approval for Rystiggo (rozanolixizumab) for the Treatment of Adults with Generalized Myasthenia Gravis (gMG)

UCB Receives the EC’s Approval for Rystiggo (rozanolixizumab) for the Treatment of Adults with Generalized Myasthenia Gravis (gMG)

January 8, 2024

UCB’s Zilbrysq (zilucoplan) Receives Approval from the EC to Treat Generalized Myasthenia Gravis (gMG)

UCB’s Zilbrysq (zilucoplan) Receives Approval from the EC to Treat Generalized Myasthenia Gravis (gMG)

December 4, 2023

argenx’s Vyvgart with Halozyme’s Enhanze Receives the EC’s Approval for the Treatment of Generalized Myasthenia Gravis

argenx’s Vyvgart with Halozyme’s Enhanze Receives the EC’s Approval for the Treatment of Generalized Myasthenia Gravis

November 17, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us